What is the difference between Cagrilintide and Pramlintide?

Cagrilintide is classified as: Long-acting amylin (and calcitonin) receptor agonist / amylin analogue. Pramlintide is classified as: Synthetic amylin analog (amylinomimetic). Cagrilintide is investigational and is not an approved medicine. Pramlintide is approved for one or more medical uses in at least one major jurisdiction.

Is Cagrilintide or Pramlintide approved?

Cagrilintide is investigational and is not an approved medicine. Pramlintide is approved for one or more medical uses in at least one major jurisdiction. Regulatory status by region is set out in the table above.

How much clinical trial evidence is tracked for Cagrilintide and Pramlintide?

Peptide Science Daily tracks 42 registered clinical trials for Cagrilintide (evidence grade B) and 64 for Pramlintide (evidence grade A).

Compound comparison

Cagrilintide vs Pramlintide

This page sets Cagrilintide and Pramlintide side by side using the data recorded on Peptide Science Daily: drug class, mechanism of action, regulatory status by region, the evidence grade assigned here, and the number of clinical trials tracked. It is a neutral, factual comparison and does not rank either compound or recommend one over the other.

Side-by-side comparison

Class: Cagrilintide
Long-acting amylin (and calcitonin) receptor agonist / amylin analogue
Pramlintide
Synthetic amylin analog (amylinomimetic)
Mechanism: Cagrilintide
In plain terms, cagrilintide mimics amylin, a hormone released with insulin that promotes fullness and slows digestion.
Pramlintide
In plain terms, pramlintide mimics amylin, a hormone the pancreas normally releases together with insulin at meals.
United States (FDA): Cagrilintide
Investigational; not approved as a standalone product. As part of the CagriSema combination (with semaglutide), a new drug application has been filed and an FDA decision is expected later in 2026.
Pramlintide
Approved. Initial U.S. approval 2005 (Symlin, NDA 021332) as an adjunct to mealtime insulin in adults with type 1 or type 2 diabetes who have failed to achieve glycemic control despite optimal insulin therapy. The label carries a boxed warning for insulin-induced severe hypoglycemia.
European Union (EMA): Cagrilintide
Not authorized; investigational, no marketing authorization.
Pramlintide
Not authorized. Pramlintide does not hold an EMA marketing authorisation and is not marketed in the European Union.
Australia (TGA): Cagrilintide
Not entered on the ARTG; investigational only and not approved for supply.
Pramlintide
Not registered on the Australian Register of Therapeutic Goods (ARTG); pramlintide is not marketed as a registered medicine in Australia.
WADA: Cagrilintide
Not listed on the WADA Prohibited List. Amylin analogues are not banned substances; as an investigational agent it falls outside approved therapeutic use.
Pramlintide
Not listed on the WADA Prohibited List and not in the 2026 Monitoring Program. An amylin analog is not prohibited in or out of competition.
Evidence grade: Cagrilintide
B
Pramlintide
A
Tracked clinical trials: Cagrilintide
42
Pramlintide
64
Full profile: Cagrilintide
Cagrilintide profile
Pramlintide
Pramlintide profile

Comparison of Cagrilintide and Pramlintide by class, mechanism, regulatory status by region, evidence grade, and number of tracked clinical trials.
Attribute	Cagrilintide	Pramlintide
Class	Long-acting amylin (and calcitonin) receptor agonist / amylin analogue	Synthetic amylin analog (amylinomimetic)
Mechanism	In plain terms, cagrilintide mimics amylin, a hormone released with insulin that promotes fullness and slows digestion.	In plain terms, pramlintide mimics amylin, a hormone the pancreas normally releases together with insulin at meals.
United States (FDA)	Investigational; not approved as a standalone product. As part of the CagriSema combination (with semaglutide), a new drug application has been filed and an FDA decision is expected later in 2026.	Approved. Initial U.S. approval 2005 (Symlin, NDA 021332) as an adjunct to mealtime insulin in adults with type 1 or type 2 diabetes who have failed to achieve glycemic control despite optimal insulin therapy. The label carries a boxed warning for insulin-induced severe hypoglycemia.
European Union (EMA)	Not authorized; investigational, no marketing authorization.	Not authorized. Pramlintide does not hold an EMA marketing authorisation and is not marketed in the European Union.
Australia (TGA)	Not entered on the ARTG; investigational only and not approved for supply.	Not registered on the Australian Register of Therapeutic Goods (ARTG); pramlintide is not marketed as a registered medicine in Australia.
WADA	Not listed on the WADA Prohibited List. Amylin analogues are not banned substances; as an investigational agent it falls outside approved therapeutic use.	Not listed on the WADA Prohibited List and not in the 2026 Monitoring Program. An amylin analog is not prohibited in or out of competition.
Evidence grade	B	A
Tracked clinical trials	42	64
Full profile	Cagrilintide profile	Pramlintide profile

Common questions

What is the difference between Cagrilintide and Pramlintide?: Cagrilintide is classified as: Long-acting amylin (and calcitonin) receptor agonist / amylin analogue. Pramlintide is classified as: Synthetic amylin analog (amylinomimetic). Cagrilintide is investigational and is not an approved medicine. Pramlintide is approved for one or more medical uses in at least one major jurisdiction.
Is Cagrilintide or Pramlintide approved?: Cagrilintide is investigational and is not an approved medicine. Pramlintide is approved for one or more medical uses in at least one major jurisdiction. Regulatory status by region is set out in the table above.
How much clinical trial evidence is tracked for Cagrilintide and Pramlintide?: Peptide Science Daily tracks 42 registered clinical trials for Cagrilintide (evidence grade B) and 64 for Pramlintide (evidence grade A).